ReviewGastroenterology and hepatology from bed to bench2017
Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment.
Review in Gastroenterology and hepatology from bed to bench, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04284878 (Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease), which is not on this map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cross talk between bacterial and human gene networks enriched using ncRNAs in IBD disease.Scientific reports · 2023Pooled it
- Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials.European journal of nutrition · 2021Pooled it
- The effects of extra virgin olive oil and canola oil on inflammatory markers and gastrointestinal symptoms in patients with ulcerative colitis.European journal of clinical nutrition · 2020Trial
- Potential Role of Circulating miR-103a, miR-145 and miR-191 as Diagnostic Biomarkers for Ulcerative Colitis and Crohn's Disease.International journal of molecular sciences · 2025Article
- Advances in biosensors for diagnosis and monitoring of inflammatory bowel disease: A review.Bioengineering & translational medicine · 2025Review
- Diagnostic Potential of Periostin, Galectin-3 and Tenascin C Serum Measurements in Inflammatory Bowel Disease: Pilot Study.International journal of molecular sciences · 2025Article
- Neutrophil Elastase and Elafin in Inflammatory Bowel Diseases: Urinary Biomarkers Reflecting Intestinal Barrier Dysfunction and Proteolytic Activity.Journal of clinical medicine · 2025Article
- Insight of Intestinal Fatty Acid Binding Protein as a Potential Biomarker in the Biology of Epithelial Damage of Gastrointestinal Membrane.Current protein & peptide science · 2025Review
- New Role of the Serotonin as a Biomarker of Gut-Brain Interaction.Life (Basel, Switzerland) · 2024Review
- Article
- M1 intestinal macrophages-derived exosomes promote colitis progression and mucosal barrier injury.Aging · 2024Article
- ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery.BMC bioinformatics · 2023Article
- Hypoxia in the Pathophysiology of Inflammatory Bowel Disease.Comprehensive Physiology · 2023Article
- Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study.Journal of Yeungnam medical science · 2023Article
- Epigenetic regulation and therapeutic strategies in ulcerative colitis.Frontiers in genetics · 2023Review
- Characterization of serum polyunsaturated fatty acid profile in patients with inflammatory bowel disease.Therapeutic advances in chronic disease · 2023Article
- Protective effects of amoxicillin and probiotics on colon disorders in an experimental model of acute diverticulitis disease.Inflammopharmacology · 2022Article
- Inflammatory bowel disease biomarkers.Medicinal research reviews · 2022Review
- Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's Disease.Inflammatory bowel diseases · 2022Article
- Bifidobacterium BLa80 mitigates colitis by altering gut microbiota and alleviating inflammation.AMB Express · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic disease of unknown etiology which mostly involves the intestine and requires a personalized approach for treatment. IBD represents a heterogeneous group of patients with inherently variable disease courses. Hence, the heterogeneity of patient populations may delay the diagnosis, clinical practice and initiation of appropriate treatment. Use of biomarkers for diagnosis and management of IBD is still necessary. Descriptions of the immunological pathway abnormalities in IBD improve assessment to identify the patient's disease status, and relative risk of progression to complicated disease behaviors, and this information may ultimately influence therapeutic decisions. In this study, we try to explain the role of biomarkers in early diagnosis, estimating prognosis, and target agents for correct managements of IBD's patients. This information might be important to provide insight into emerging panels of multiple IBD biomarkers and highlighting the essential role of personalizes panel for each patient.
Indexed as
Identifiers
29118930PMC5660264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.